Rashmi Gopal-Srivastava | Dir, Extramural Research Program, Office Rare Diseases
National Institutes of Health

Rashmi Gopal-Srivastava, Dir, Extramural Research Program, Office Rare Diseases, National Institutes of Health

Currently Dr. Gopal-Srivastava she is the Director of Extramural Research Program in the Office of Rare Diseases Research (ORDR) of  National Center for Advancing Translational Science (NCATS), at the NIH, USA since 2006. She oversees the national program on Rare Diseases Clinical Research Network (RDCRN). The RDCRN consists of 22 consortia and a central Data Management Coordinating Center. RDCRN has more than 200 participating sites (including 17 countries), 130 plus Patient Advocacy Groups as research partners, and conducts research on ~280 rare diseases.  She is responsible for developing and expanding the extramural research program to coordinate research activities on rare diseases in collaboration with other Federal Agencies, patient advocates, and other organizations.  She has also served as the acting program officer for three academic institutions with Clinical and Translational Sciences Awards (CTSA), another national program at NCATS. She is collaborating with FDA on Medical Devices for Rare Diseases Needs Assessment Project.

Dr. Gopal-Srivastava joined the National Institutes of  Health (NIH), USA in 1989 as a laboratory investigator, and then extramural program at NIH as a program director since 1998. Prior to her current position she served as the program director for breast cancer  translational research program SPOREs (Specialized program of Research Excellence) at the National Cancer Institute (NCI), NIH.  She received her doctorate degree in Microbiology and Immunology from the Medical College of Virginia, Virginia Commonwealth University in 1989 and received a Virginia Commonwealth fellowship. The same year she was selected and awarded a Research Associate ship from the US National Research Council of the National Academies Science, and joined the Laboratory of Molecular and Developmental Biology at the National Eye Institute, NIH and conducted research on regulation of gene expression for alphaB-cystallin (small heat shock protein). She has published several papers in peer-reviewed journals, written book chapters and delivered invited oral presentations nationally and internationally.

Dr. Gopal-Srivastava has received several honors and awards including NIH Merit Award and is a member of a number of scientific committees. She has served on several NIH Committees such as NCI Working Group for response to NCI Breast Cancer Progress Review Recommendations, NIH Road Map 1.5 Protein Capture/proteome Working Group and as Chairperson, Subgroup on Characterization and Validation and as NCI Representative for Brain Tumor Progress Review Group Meetings. Currently she is a member of Federal Working Group on Dietary Supplements, NIH Nanotechnology Task Force, Trans-NIH Coordinating Committee for Lymphatic Research and Trans NIH Rare Diseases Working Group. She has actively participated as invited panel member for many workshops/meetings. e.g. TransMed Partner Forum Inaugural Meeting: Defining Success in Translational Medicine, Vitamin and Cofactor Therapy and Clinical Trials for Mitochondrial Diseases, Mitochondrial Mini Symposium, Conference on Clinical Research for Rare Diseases and Program faculty for the Workshop “Accelerating Anti Cancer Agent Development and Validation”, a workshop for clinical and translational cancer investigators, sponsored by American Association of Cancer Research, NCI, Food and Drug Administration, American Association of Cancer Oncology and Duke Cancer Center. 

back to speakers